Papers/PMID:19436941
Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2010The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
strontium(2+) — decreases vertebral fracture incidence
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“Strontium ranelate was associated with a reduction in the relative risk of vertebral fracture, relative to placebo, of 40% (RR = 0.60, 95% CI [0.53–0.70], p < 0.001).”
Quoted verbatim from Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover.. - Study
- RCT
- Dose
- strontium ranelate 2 g/day
- Population
- Post-menopausal women with osteoporosis, pooled from the SOTI and TROPOS randomised placebo-controlled trials; calcium and vitamin D supplements given to both arms; 3-year vertebral fracture data
Effect 0.6 risk ratio, 95% CI 0.53 to 0.7
Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover.2010PMID:19436941Permalink